BCIQ Profiles

Company Profile Report
0715 QTs
BioCentury & Getty Images


July 15 Quick Takes: FDA panel rebuffs FibroGen CKD program; plus PAQ, Galapagos, Adlai Nortye and Ablynx-LabGenius

Jul 15, 2021 | 11:56 PM GMT

In light of concerns over roxadustat’s cardiovascular safety risks, FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 13-1 against approval of

Read the full 476 word article

How to gain access

Continue reading with a
two-week free trial.